These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 25823534)

  • 1. Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
    Inthachai T; Lekawanvijit S; Kumfu S; Apaijai N; Pongkan W; Chattipakorn SC; Chattipakorn N
    Exp Physiol; 2015 Jun; 100(6):667-79. PubMed ID: 25823534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction.
    Apaijai N; Inthachai T; Lekawanvijit S; Chattipakorn SC; Chattipakorn N
    J Endocrinol; 2016 Jun; 229(3):245-58. PubMed ID: 27044778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats.
    Murase H; Kuno A; Miki T; Tanno M; Yano T; Kouzu H; Ishikawa S; Tobisawa T; Ogasawara M; Nishizawa K; Miura T
    Cardiovasc Diabetol; 2015 Aug; 14():103. PubMed ID: 26259714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.
    Yin M; Silljé HH; Meissner M; van Gilst WH; de Boer RA
    Cardiovasc Diabetol; 2011 Sep; 10():85. PubMed ID: 21955567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
    Apaijai N; Chinda K; Palee S; Chattipakorn S; Chattipakorn N
    PLoS One; 2014; 9(7):e102374. PubMed ID: 25036861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats.
    Sivasinprasasn S; Sa-Nguanmoo P; Pongkan W; Pratchayasakul W; Chattipakorn SC; Chattipakorn N
    Menopause; 2016 Aug; 23(8):894-902. PubMed ID: 27326818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats.
    Tanajak P; Pintana H; Siri-Angkul N; Khamseekaew J; Apaijai N; Chattipakorn SC; Chattipakorn N
    J Endocrinol; 2017 Feb; 232(2):189-204. PubMed ID: 27875248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vildagliptin reduces cardiac ischemic-reperfusion injury in obese orchiectomized rats.
    Pongkan W; Pintana H; Jaiwongkam T; Kredphoo S; Sivasinprasasn S; Chattipakorn SC; Chattipakorn N
    J Endocrinol; 2016 Oct; 231(1):81-95. PubMed ID: 27543302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
    Hausenloy DJ; Whittington HJ; Wynne AM; Begum SS; Theodorou L; Riksen N; Mocanu MM; Yellon DM
    Cardiovasc Diabetol; 2013 Oct; 12():154. PubMed ID: 24148218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
    Apaijai N; Pintana H; Chattipakorn SC; Chattipakorn N
    Br J Pharmacol; 2013 Jul; 169(5):1048-57. PubMed ID: 23488656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP-4 Inhibitor and Estrogen Share Similar Efficacy Against Cardiac Ischemic-Reperfusion Injury in Obese-Insulin Resistant and Estrogen-Deprived Female Rats.
    Sivasinprasasn S; Tanajak P; Pongkan W; Pratchayasakul W; Chattipakorn SC; Chattipakorn N
    Sci Rep; 2017 Mar; 7():44306. PubMed ID: 28281660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.
    Apaijai N; Pintana H; Chattipakorn SC; Chattipakorn N
    Endocrinology; 2012 Aug; 153(8):3878-85. PubMed ID: 22621958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice.
    Takahashi A; Asakura M; Ito S; Min KD; Shindo K; Yan Y; Liao Y; Yamazaki S; Sanada S; Asano Y; Ishibashi-Ueda H; Takashima S; Minamino T; Asanuma H; Mochizuki N; Kitakaze M
    Am J Physiol Heart Circ Physiol; 2013 May; 304(10):H1361-9. PubMed ID: 23504176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart.
    Chinda K; Sanit J; Chattipakorn S; Chattipakorn N
    Diab Vasc Dis Res; 2014 Mar; 11(2):75-83. PubMed ID: 24357666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
    Yamaguchi T; Watanabe A; Tanaka M; Shiota M; Osada-Oka M; Sano S; Yoshiyama M; Miura K; Kitajima S; Matsunaga S; Tomita S; Iwao H; Izumi Y
    J Pharmacol Sci; 2019 Feb; 139(2):112-119. PubMed ID: 30638989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of continuous infusion of brain natriuretic peptides on postmyocardial infarction ventricular remodelling in rats.
    Pan Y; Zhu W; Ma J; Xin P; Han B; He Y; Wang Y; Peng T; Wei M
    Arch Cardiovasc Dis; 2011 Jan; 104(1):17-28. PubMed ID: 21276574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
    Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
    Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats.
    Tanajak P; Sa-Nguanmoo P; Apaijai N; Wang X; Liang G; Li X; Jiang C; Chattipakorn SC; Chattipakorn N
    Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28391633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury.
    Chinda K; Palee S; Surinkaew S; Phornphutkul M; Chattipakorn S; Chattipakorn N
    Int J Cardiol; 2013 Jul; 167(2):451-7. PubMed ID: 22285447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase-4 inhibitor enhances restoration of salivary glands impaired by obese-insulin resistance.
    Ittichaicharoen J; Apaijai N; Tanajak P; Sa-Nguanmoo P; Chattipakorn N; Chattipakorn S
    Arch Oral Biol; 2018 Jan; 85():148-153. PubMed ID: 29073562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.